



THE VERONA FIRM PLLC

P.O. Box 18191

Tampa, Florida 33679

(813) 258-0852

brett@theveronafirm.com

TheVeronaFirm.com

Thursday, February 29, 2024

OTC Markets Group, LLC
300 Vesey Street, 12th Floor
New York, New York 10282

RE: Opinion of Counsel regarding Adequate Current Information for Sante Technology Holdings, Inc. for fiscal year ended December 31, 2022 through September 30, 2023

The Verona Firm, PLLC been retained in order to provide this Opinion of Counsel to Sante Technology Holdings, Inc. (the “Company”), a Nevada corporation with its principal office in Thousand Oaks, California. Neither this firm nor any attorney in this firm owns any shares of the Companies securities, and there is no agreement to receive shares of the Company for this firms’ services. Brett Verona is the individual responsible for drafting this letter, and is a resident of the State of Florida, and licensed to practice law in the state of Florida.

I have been requested to render a sufficiency of adequate current information opinion (this “Opinion”) in connection with the filing of an Annual Report for the period ended December 31, 2022, inclusive of the Quarterly Reports through the period ended September 30, 2023, and other reports previously filed or uploaded to www.otcmarkets.com by the Company pursuant to the applicable Rules of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended.

In preparing this Opinion of Counsel, I have applied the applicable laws of the State of Florida (where I am licensed) and of the United States, regarding its corporate operations and level of disclosure of corporate information with regard to the Pink OTC Markets Disclosure Guidelines.

In the course of preparing this Opinion, counsel has reviewed the following documents (the “Documents”) relating to the Company as follows:

PUBLISH DATE	TITLE	PERIOD END DATE
02/27/2024	Quarterly Report – Amendment No. 4	9/30/2023
02/27/2024	Quarterly Report – Amendment No. 5	6/30/2023

02/27/2024	Quarterly Report – Amendment No. 5	3/31/2023
------------	---------------------------------------	-----------

02/27/2024	Annual Report – Amendment No. 5	12/31/2022
------------	------------------------------------	------------

Counsel has also examined other related corporate information as necessary and information provided by the Company's management for the purposes of this letter. As to matters of fact, this firm has relied upon information obtained from the officers and directors of the Company, and other sources, and those sources are believed to be reliable. In rendering this opinion, I have examined and relied upon oral representations and documents provided to me by the Transfer Agent, the Company, and public records as well. I have assumed that (i) all statements and representations contained therein were accurate and truthful; (ii) all documents submitted to me were true and accurate; (iii) all signatures contained on any documents were genuine; (iv) all persons who signed documents had the legal capacity to do so; and (v) all original documents conform with all the documents submitted to me. The opinions and conclusions contained in this Opinion are based upon documentation and facts made available to this firm and are solely based on the accuracy of those documents and facts.

Further, counsel has reviewed the prior disclosures posted by the Company with OTC Disclosure and News Service. All such information, as updated and revised in the most recently filed amended filings for the period in question, is believed to be accurate and reliable. In the event that the facts and information in any or all of such documents are determined not to be true, this opinion is rescinded and to be deemed null and void. Counsel has discussed the above documentation, and the underlying assumptions this firm is relying upon, with the management of the Company.

Additionally, counsel has personally conferred via Zoom with the Companies present management specifically: Zongjiang He the Company's Chief Executive Officer, Treasurer and Director, and Yiyu Peng, the Company's Secretary and Director, to discuss the information contained in the Company's disclosure statements. The party responsible for the preparation of the unaudited financial statements of the Company is Jingxing Li, a Consultant and Technical Director (though not a Board Member) of the Company. Jingxing Li has a degree in Accounting from Shanghai Maritime University and an MBA from Canisius College. He has 39 years of accounting experience, including 25 years of experience in preparing financial statements for several listed Companies in Hong Kong, China and the United States.

The Company has 500,000,000 (Five Hundred Million) authorized common shares of which 238,865,918 (Two Hundred Thirty-Eight Million, Eight Hundred Sixty-Five Thousand, Nine Hundred Eighteen) shares are issued and outstanding as of February 15, 2024, which is the same as they indicated in their most recent filing for the period ended September 30, 2023. Further, the Company has Preferred Stock, of which 10,000,000 (Ten Million) shares are authorized and 10,000,000 (Ten Million) are outstanding. The Company's fiscal year end date is December 31.

The Company's Transfer Agent for their common stock and preferred stock is Issuer Direct Corporation with an address at One Glenwood Avenue, Suite 1001, Raleigh, NC 27603 and their phone number is (919) 877-6051. An inquiry to the transfer agent was the source of confirmation of the Company's common and preferred shares outstanding. Additionally, a search of the SEC's EDGAR system confirmed that Issuer Direct Corporation. is a registered transfer agent.

Further, to inquiry of management and directors of the corporation, to the best of this firm's knowledge, neither the Company nor any person or entity holding at least five percent (5%) of the corporation's stock has not been, nor is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities law.

The Company has been a shell company as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the Securities Exchange Act of 1934, as disclosed in their public filings.

No person or entity other than OTC Markets is entitled to rely upon this opinion. OTC Markets, however, is granted full and complete permission and rights to publish this document via the OTC Disclosure and News Service for viewing by the general public and regulators. The OTC Markets Group may rely on the above in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933. The information which has been posted via OTC Disclosure and News Service constitutes adequate current public information is available within the meaning of S.E.C. Rule 144(c)(2) of the Securities Act, includes all the information that a broker-dealer would be required to obtain from an issuer in order to publish a quotation for its securities pursuant to Rule 15c2-11 under the Securities Exchange Act of 1934, and complies as to form with the OTC Markets Guidelines for Providing Adequate Current Information.

The opinions expressed herein are in reference to the laws of Florida and where applicable to the laws of the United States. The undersigned counsel is permitted to practice before the Securities and Exchange Commission and has not been prohibited from practice before the Commission. Counsel is not currently, nor has in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency. Additionally, during the last five years counsel has not been suspended or barred from practicing in any state or jurisdiction and has not been charged in a civil or criminal case.

Kind regards.

DocuSigned by:

8A1BDB770CEE47B...

Brett Verona